Microbiome Labs acquired by Novozymes
Novozymes agreed to acquire Microbiome Labs, a US probiotics / microbiome supplements brand, on Jan 6, 2021.
Transaction summary
- Target
- Microbiome Labs
- Acquirer
- Novozymes
- Seller
- -
- Announced
- 2021-01-06
- Geography
- United States
- Tags
- CPGMicrobiome SupplementsProbioticsProbiotics / Microbiome Supplements
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
100% enterprise value
USD 125M
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
3.1x
Period not stated
Basis: FundComb estimate
EV / EBITDA
6x
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Consideration: USD 125M
US$125 million headline value from Google News RSS result for NutraIngredients.com article; full article was not fetched and no primary-source value was supplied.
Basis
- USD 125m consideration is treated as publicly disclosed or derived directly from public source data.
- Valuation covers 100% of the target; the amount invested or paid for a stake is separate.
- EV / revenue: 3.1x.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Source summary
No public source summary has been published for this transaction yet.